| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.098 | 0.006 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.006 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.14 | 0.006 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.007 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.007 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | -0.092 | 0.007 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.008 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | -0.079 | 0.009 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.095 | 0.009 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | 0.16 | 0.009 |